Novo Nordisk A/S

🇩🇰Denmark

Country: 🇩🇰Denmark

Ownership: Public

Established: 1923-01-01

Employees: 63.3K

Market Cap: $602.2B

Website: http://www.novonordisk.com

Clinical Trials

A Trial Investigating the Safety, Tolerability, Pharmacokinetics (the Exposure of the Trial Drug in the Body) and Pharmacodynamics (the Effect of the Investigated Drug on the Body) of Insulin 287 in Subjects With Type 2 Diabetes

Phase 1

Completed

Conditions: Diabetes
Diabetes Mellitus, Type 2

Interventions: Drug: insulin degludec
Drug: Insulin icodec
Drug: placebo

First Posted Date: 2016-11-15

Last Posted Date: 2021-08-27

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 50

Registration Number: NCT02964104

Locations: 🇩🇪
Novo Nordisk Investigational Site, Neuss, Germany

Effect and Safety of Liraglutide 3.0 mg as an Adjunct to Intensive Behaviour Therapy for Obesity in a Non-specialist Setting

Phase 3

Completed

Conditions: Metabolism and Nutrition Disorder
Obesity

Interventions: Drug: placebo
Drug: liraglutide
Behavioral: CMS Intensive Behavior Therapy

First Posted Date: 2016-11-15

Last Posted Date: 2020-03-11

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 282

Registration Number: NCT02963935

Locations: 🇺🇸
Novo Nordisk Investigational Site, Arlington, Virginia, United States

A Trial Investigating the Absorption, Metabolism and Excretion of Somapacitan After Single Dosing in Healthy Male Subjects

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: somapacitan

First Posted Date: 2016-11-11

Last Posted Date: 2017-06-07

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 7

Registration Number: NCT02962440

Locations: 🇳🇱
Novo Nordisk Investigational Site, Groningen, Netherlands

Investigation of Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Dosing of NNC0174-0833 in Subjects With Obesity or Overweight

Phase 1

Completed

Conditions: Obesity
Metabolism and Nutrition Disorder

Interventions: Drug: NNC0174-0833
Drug: Placebo

First Posted Date: 2016-11-08

Last Posted Date: 2018-02-01

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 96

Registration Number: NCT02958085

Locations: 🇺🇸
Novo Nordisk Investigational Site, Overland Park, Kansas, United States

A First Human Dose Trial Investigating Safety, Tolerability and Pharmacokinetics for Single Doses of NNC9204-1177 in Subjects Being Overweight or With Obesity.

Phase 1

Completed

Conditions: Obesity
Metabolism and Nutrition Disorder

Interventions: Drug: NNC9204-1177
Drug: Placebo

First Posted Date: 2016-10-21

Last Posted Date: 2018-09-05

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 49

Registration Number: NCT02941042

Locations: 🇺🇸
Novo Nordisk Investigational Site, Baltimore, Maryland, United States

Evaluating the Pharmacokinetics of NovoEight® (Turoctocog Alfa) in Relation to BMI in Subjects With Haemophilia A

Phase 1

Completed

Conditions: Congenital Bleeding Disorder
Haemophilia A

Interventions: Drug: turoctocog alfa

First Posted Date: 2016-10-21

Last Posted Date: 2019-01-30

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 35

Registration Number: NCT02941354

Locations: 🇨🇳
Novo Nordisk Investigational Site, Taipei, Taiwan

A Randomised Proof-of-Principle Trial Investigating Pharmacodynamics, Pharmacokinetics, and Safety of NNC0143-0406 in Subjects With Type 1 Diabetes Mellitus

Phase 1

Completed

Conditions: Diabetes
Diabetes Mellitus, Type 1

Interventions: Drug: NNC0143-0406
Drug: Insulin Aspart

First Posted Date: 2016-10-19

Last Posted Date: 2018-02-26

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 47

Registration Number: NCT02938572

Locations: 🇦🇹
Novo Nordisk Investigational Site, Graz, Austria

Efficacy and Safety of Turoctocog Alfa for Prophylaxis and Treatment of Bleeding Episodes in Previously Treated Chinese Patients With Haemophilia A

Phase 3

Completed

Conditions: Congenital Bleeding Disorder
Haemophilia A

Interventions: Drug: turoctocog alfa

First Posted Date: 2016-10-19

Last Posted Date: 2020-07-27

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 68

Registration Number: NCT02938585

Locations: 🇨🇳
Novo Nordisk Investigational Site, Hangzhou, Zhejiang, China

A Trial Investigating the Pharmacokinetic and Pharmacodynamic Properties of Faster-acting Insulin Aspart in Subjects With Type 2 Diabetes Mellitus

Phase 1

Completed

Conditions: Diabetes
Diabetes Mellitus, Type 2

Interventions: Drug: Faster-acting insulin aspart
Drug: Insulin Aspart

First Posted Date: 2016-10-14

Last Posted Date: 2019-05-24

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 61

Registration Number: NCT02933853

Locations: 🇦🇹
Novo Nordisk Investigational Site, Graz, Austria

A Multi-centre, Comparative, Double Blind, Randomised Cross-over Trial Investigating Single Dose Pharmacokinetics and Safety of Turoctocog Alfa Pegol From the Pivotal Process and Turoctocog Alfa Pegol From the Commercial Process in Patients With Severe Haemophilia A

Phase 1

Completed

Conditions: Congenital Bleeding Disorder
Haemophilia A

Interventions: Drug: turoctocog alfa pegol

First Posted Date: 2016-09-30

Last Posted Date: 2017-12-15

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 21

Registration Number: NCT02920398

Locations: 🇪🇸
Novo Nordisk Investigational Site, Málaga, Spain

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy